4.7 Review

Current status of terpenoids as inflammasome inhibitors

Journal

BIOCHEMICAL PHARMACOLOGY
Volume 172, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2019.113739

Keywords

NLRP3-inflammasome; Terpenoids; Inflammation

Funding

  1. FIS [PI11/00036, PI14/00055, PI17/00012]
  2. ISCIII [MPY 1410/09]
  3. Spanish Ministry of Health (Instituto de Salud Carlos III) [RD12/0036/0059]
  4. Ministerio de Economia y Competitividad [RTI2018-094356-B-C21]
  5. Spanish Ministry of Education, Culture and Sports [FPU17/03519]

Ask authors/readers for more resources

Increasing evidence supports NLRP3 inflammasome as a new target to control inflammation. Dysregulation of NLRP3 inflammasome has been reported to be involved in the pathogenesis of several human inflammatory diseases. However, no NLRP3 inflammasome inhibitors are available in clinic. Terpenoids are natural products with multi-target activities against inflammation. Recent studies have revealed that these compounds are capable of inhibiting the activation of NLRP3 inflammasome in several mouse models of NLRP3 inflammasome-related pathogenesis. Thus, terpenoids represent an interesting pharmacological approach for the treatment of inflammatory diseases as they are endowed with a dual mechanism of inhibition of NF-KB transcription factor and inflammasome activation, both critically involved in their anti-inflammatory effects. This work provides an overview of the current knowledge on the therapeutic potential of terpenoids as NLRP3 inflammasome inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Ivabradine in acute heart failure: Effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial

Marina Pascual Izco, Rafael Ramirez-Carracedo, Ignacio Hernandez Navarro, Alvaro Osorio Ruiz, Borja Castejon Navarro, Irene Cuadrado Berrocal, Carlota Largo Aramburu, Gonzalo Luis Alonso Salinas, Javier Diez, Marta Saura Redondo, Jose Luis Zamorano, Carlos Zaragoza, Marcelo Sanmartin

CARDIOLOGY JOURNAL (2020)

Article Chemistry, Medicinal

Dehydroisohispanolone as a Promising NLRP3 Inhibitor Agent: Bioevaluation and Molecular Docking

Laura Gonzalez-Cofrade, Irene Cuadrado, Angel Amesty, Ana Estevez-Braun, Beatriz de las Heras, Sonsoles Hortelano

Summary: The study demonstrates that DIH effectively inhibits NLRP3 inflammasome activation in macrophages, showing potential application in treating inflammation-related diseases.

PHARMACEUTICALS (2022)

Article History

When the way becomes the core. The cinematographic avant-garde as a reflection of its time

Beatriz de las Heras

Summary: Cinema is not just an art form, but also a tool for expressing emotions and conveying information. The avant-garde films of the interwar period were not only aesthetically groundbreaking, but also served as a means of expressing the desire for change in a collapsing modern society. Today, these films have become valuable sources of knowledge that allow us to explore and understand the history of that era.

HISPANIA NOVA (2022)

Article Chemistry, Medicinal

Labdane conjugates protect cardiomyocytes from doxorubicin-induced cardiotoxicity

Irene Cuadrado, Sandra Oramas-Royo, Laura Gonzalez-Cofrade, Angel Amesty, Sonsoles Hortelano, Ana Estevez-Braun, Beatriz de las Heras

Summary: A series of new labdane conjugates were synthesized and showed cardioprotective effects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress-mediated signaling pathways and autophagy mediated by Akt activation.

DRUG DEVELOPMENT RESEARCH (2023)

Article Biochemistry & Molecular Biology

Phenolic and quinone methide nor-triterpenes as selective NLRP3 inflammasome inhibitors

Laura Gonzalez-Cofrade, Jack P. Green, Irene Cuadrado, Angel Amesty, Sandra Oramas-Royo, David Brough, Ana Estevez-Braun, Sonsoles Hortelano, Beatriz de las Heras

Summary: This study evaluated the potential anti-inflammatory activity of phenolic and quinonemethide nor-triterpenes isolated from Maytenus retusa and their derivatives through inhibition of the NLRP3 inflammasome. Triterpenes 6 and 14 showed the highest anti-inflammatory activity by significantly reducing caspase-1 activity, IL-1 beta secretion, and pyroptosis. Further characterization confirmed their selective inhibition of NLRP3 inflammasome without affecting AIM2 or NLRC4 inflammasome activation.

BIOORGANIC CHEMISTRY (2023)

Article Plant Sciences

Synthesis of Quinoline and Dihydroquinoline Embelin Derivatives as Cardioprotective Agents

Pedro Martin-Acosta, Irene Cuadrado, Laura Gonzalez-Cofrade, Roberto Pestano, Sonsoles Hortelano, Beatriz de las Heras, Ana Estevez-Braun

Summary: A set of new dihydroquinoline embelin derivatives were synthesized from the reaction of natural benzoquinone embelin with anilines and aromatic aldehydes in the presence of AgOTf. The resulting compounds showed potential as cardioprotective agents, attenuating the cardiotoxicity effect of doxorubicin on oxidative stress and apoptosis. The best activities were achieved with quinoline-embelin derivatives having a 4-nitrophenyl group attached at the pyridine ring.

JOURNAL OF NATURAL PRODUCTS (2023)

Article Biology

Visualization of Lipid Droplets in the Alveolar Macrophage Cell Line MH-S with Live-cell Imaging by 3D Holotomographic Microscopy (Nanolive)

Andrea Perez-Montero, Oscar Zaragoza, Alfonso Luque, Sonsoles Hortelano, Paloma Acebo

Summary: Lipid droplets (LD) are important lipid storage organelles with multiple biological functions. Fluorescence imaging is commonly used to visualize LD, but it can cause damage and alter organelle dynamics. This study presents a label-free method using 3D holotomographic microscopy to visualize LD accumulation in MH-S alveolar macrophages treated with oleic acid.

BIO-PROTOCOL (2023)

Meeting Abstract Respiratory System

Inflammatory profile of bronchoalveolar lavage in pulmonary Langerhans cell histiocytosis

S. Barril, D. Castillo, P. Millan, A. Luque, P. Acebo, S. Hortelano

EUROPEAN RESPIRATORY JOURNAL (2022)

Article Pharmacology & Pharmacy

Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib

Paola Orlandi, Marta Banchi, Francesca Vaglini, Marco Carli, Stefano Aringhieri, Arianna Bandini, Carla Pardini, Cristina Viaggi, Michele Lai, Greta Ali, Alessandra Ottani, Eleonora Vandini, Patrizia Guidi, Margherita Bernardeschi, Veronica La Rocca, Giulio Francia, Gabriella Fontanini, Mauro Pistello, Giada Frenzilli, Daniela Giuliani, Marco Scarselli, Guido Bocci

Summary: This study investigates the role of MC4R in melanoma and the use of the selective antagonist ML in combination with vemurafenib. The results show that ML can inhibit melanoma cell proliferation and induce apoptosis through the inhibition of ERK1/2 phosphorylation and reduction of BCL-XL expression. The combination of vemurafenib and ML exhibits a synergistic effect in vitro and inhibits tumor growth in vivo without causing adverse effects.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Cardiac human bitter taste receptors contain naturally occurring variants that alter function

Conor J. Bloxham, Katina D. Hulme, Fabrizio Fierro, Christian Fercher, Cassandra L. Pegg, Shannon L. O'Brien, Simon R. Foster, Kirsty R. Short, Sebastian G. B. Furness, Melissa E. Reichelt, Masha Y. Niv, Walter G. Thomas

Summary: Bitter taste receptors (T2Rs) are a type of G protein-coupled receptors that allow humans to detect aversive and toxic substances. This study characterized the functional properties of previously identified T2Rs in human cardiac tissues and their naturally occurring polymorphisms. The results showed differences in signaling among different T2R variants, and revealed a potential association between the T2R50 Tyr203 variant and cardiovascular disease.

BIOCHEMICAL PHARMACOLOGY (2024)

Article Pharmacology & Pharmacy

Carfilzomib suppressed LDHA-mediated metabolic reprogramming by targeting ATF3 in esophageal squamous cell carcinoma

Lu Chen, Huanying Shi, Wenxin Zhang, Yongjun Zhu, Haifei Chen, Zimei Wu, Huijie Qi, Jiafeng Liu, Mingkang Zhong, Xiaojin Shi, Tianxiao Wang, Qunyi Li

Summary: This study demonstrates that Carfilzomib exhibits potent anti-tumor activity against esophageal squamous cell carcinoma (ESCC) by triggering mitochondrial apoptosis and reprogramming cellular metabolism. It has been identified that activating transcription factor 3 (ATF3) plays a crucial role as a cellular target in ESCC cells treated with Carfilzomib. Overexpression of ATF3 effectively counteracts the effects of Carfilzomib on ESCC cell proliferation, apoptosis, and metabolic reprogramming. Furthermore, ATF3 mediates the anti-tumor activity of Carfilzomib, suggesting its potential as a therapeutic agent for ESCC.

BIOCHEMICAL PHARMACOLOGY (2024)

Review Pharmacology & Pharmacy

Ferroptosis resistance in cancer: recent advances and future perspectives

Xing Zhang, Xiang Li, Ran Xia, Hong-Sheng Zhang

Summary: This review summarizes recent progress on the mechanisms of ferroptosis resistance in cancer and highlights the role of redox status and metabolism. Combination therapy for ferroptosis has great potential in treating resistant malignant tumors.

BIOCHEMICAL PHARMACOLOGY (2024)